A physician's perseverance uncovers problems in a key nephrology study

Kidney International

Volumn 82, Issue 2, 2012, Pages 135-137

  Fishbane, Steven ^a   Wish, Jay B ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DECISION MAKING; FOLLOW UP; HEART DISEASE; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84863302351     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.122     Document Type: Note

References (11)

1. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the normal hematocrit trial. K idney Int 2012; 82: 235-241.
2. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
3. Outcomes and estimation. CONSORT: Transparent Reporting of Trials (http://www.consort-statement. org/consort-statement/13-19-results/item17a- outcomes-and-estimation/) (accessed 12 January 2012).
4. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Kidney Disease Outcomes Quality Initiative, National Kidney Foundation (http://www.kidney.org/professionals/ kdoqi/guidelines-anemia/pdf/AnemiaInCKD.pdf) (accessed 12 January 2012).
5. NKF KDOQI Guidelines. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target (http://www.kidney.org/professionals/KDOQI/guidelines-anemiaUP/index. htm) (2007, accessed 12 January 2012) .
6. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
7. Dr üeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
8. Davidoff F, DeAngelis CD, Drazen JM et al. Sponsorship, authorship, and accountability. N Engl J Med 2001; 345: 825-826.
9. Fontanarosa PB, Flanagin A, DeAngelis CD. Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA 2005; 294: 110-111.
10. The CONSORT Statement. CONSORT: Transparent Reporting of Trials (http://www.consort-statement. org/consort-statement/) (accessed 10 January 2012).
11. P ROCRIT (epoetin alfa) prescribing information. Amgen: Thousand Oaks, CA, 2011 (http://www. procrit.com/sites/default/files/pdf/ProcritBooklet. pdf) .